HOME >> BIOLOGY >> NEWS
FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis

South San Francisco, CA, and Berkeley, CA Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection.

"Today's FDA approval of RAPTIVA underscores our commitment to delivering innovative therapies to patients with unmet medical needs," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "Through our collaboration with XOMA, the clinical trial investigators and most importantly, the over 2,700 patients who participated in our clinical trials, we are proud to offer a new therapeutic option to help patients manage this chronic disease."

"RAPTIVA represents XOMA's first product approval and is the culmination of a highly successful collaboration with Genentech," said John L. Castello, XOMA's chairman, president and chief executive officer. "The companies have worked together on a robust clinical program that has demonstrated the safety and efficacy of RAPTIVA. We view RAPTIVA now being available to
patients as a worthy testament to the confidence of our shareholders and the hard work and support of both companies'
employees."

"I've been treating psoriasis for over 15 years and have always been frustrated by the limited options available to treat patients with this chronic disease. Safety limitations of traditional therapies have made it difficult to offer patients continuous relief," said Craig Leonardi, M.D., clinical associate professor of dermatology of Saint Louis University, St. Louis, Mo. and a RAPTIVA clinical investigator. "RAPTIVA
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
585-256-0195
Ketchum
27-Oct-2003


Page: 1 2 3 4 5 6

Related biology news :

1. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition
2. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
3. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia
4. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
5. DFG approves 14 new research training units
6. National Science Board approves five new NSF Science and Technology Centers
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Results from open-label Raptiva study suggest continued benefit with long-term treatment
9. Genes appear to play a role in development of chronic obstructive pulmonary disease
10. New research supports theory that indirect transmission of chronic wasting disease
11. Animal studies show promise treating severe chronic pain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/1/2018)... (PRWEB) , ... August 01, 2018 , ... ... staff NP, PA’s, RN’s, LPN’s, MA's and Administrative staff. , This full day ... all the biologics. The course will expose your staff to regenerative medicine procedures ...
(Date:7/31/2018)... ... July 31, 2018 , ... Lifecycle Biotechnologies, a leading life ... In this role, Mr. Muzek will lead the company-wide industrial strategic business development ... , With over 20 years in business development, Mr. Muzek previously served ...
(Date:7/28/2018)... ... 2018 , ... Inthirani Arul, an evidence-based healer, today announces research results based ... autoimmune disorders. , Biomarkers for immune function, blood, as well as, inflammation, were ... 110% increase in overall immunity as seen by the rise in antibody levels , ...
Breaking Biology News(10 mins):
(Date:7/24/2018)... , ... July 23, 2018 , ... ... a biofield energy treated nutraceutical to increase immunity and improve anti-inflammatory, and immune ... function response assessed in the preclinical research were significantly reduced. Results are as ...
(Date:7/24/2018)... ... July 24, 2018 , ... On ... highly successful SmartTRAK platform. Not just a pretty face, SmartTRAK 3.0’s latest ... , SmartTRAK is the world’s first online and real-time data portal that ...
(Date:7/22/2018)... ... 19, 2018 , ... The Center for Advancing Innovation (CAI) ... the Laura and John Arnold Foundation and MedImmune. The overarching goal of this ... 55 institutions, including the National Institutes of Health, the United States Army, and ...
(Date:10/13/2017)... OF PRUSSIA, PA (PRWEB) , ... October 13, 2017 , ... ... Vice President and Turesol Business Unit Leader, will moderate a discussion on the subject ... year’s ISPE Annual Meeting & Expo . The theme of this year’s meeting ...
Breaking Biology Technology:
Cached News: